Combination immunotherapy with prostate GVAX and ipilimumab: safety and toxicity

Immunotherapy ◽  
2012 ◽  
Vol 4 (6) ◽  
pp. 577-580 ◽  
Author(s):  
Dev Karan ◽  
Peter Van Veldhuizen
Keyword(s):  
Combination Immunotherapy ◽  
Safety And Toxicity ◽  
Prostate Gvax

Abstract #218: An Unusual Case of Insulin Resistance Type B and its Successful Treatment with Combination Immunotherapy

2017 ◽  
Vol 23 ◽  
pp. 38-39
Author(s):  
Sheetal Malhotra ◽  
Shanaz Sikder ◽  
Elaine Cochran ◽  
Mattingly Megan ◽  
Gorden Phillip ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Successful Treatment ◽  
Unusual Case ◽  
Combination Immunotherapy ◽  
Type B

Combination immunotherapy strategies for glioblastoma

2021 ◽  
Vol 151 (3) ◽  
pp. 375-391
Author(s):  
Hok Yee Chan ◽  
John Choi ◽  
Christina Jackson ◽  
Michael Lim
Keyword(s):  
Combination Immunotherapy

scholarly journals Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538

2021 ◽  
Vol 10 (1) ◽  
pp. 1908771
Author(s):  
Oliver Klein ◽  
Clare Senko ◽  
Matteo S Carlino ◽  
Ben Markman ◽  
Louise Jackett ◽  
...  
Keyword(s):  
Subgroup Analysis ◽  
Adrenocortical Carcinoma ◽  
Combination Immunotherapy

scholarly journals 453 Novel combination immunotherapy for boosting and priming immune responses in pancreatic cancer: strong anti-tumour effects with interleukin-15 and CD40 agonist treatment

2020 ◽  
Vol 8 (Suppl 3) ◽  
pp. A480-A480
Author(s):  
Jonas Van Audenaerde ◽  
Elly Marcq ◽  
Bianca von Scheidt ◽  
Ashleigh Davey ◽  
Amanda Oliver ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
T Cells ◽  
Dendritic Cells ◽  
Natural Killer ◽  
Mouse Models ◽  
Cd8 T Cells ◽  
Tumour Growth ◽  
Immune Memory ◽  
Combination Immunotherapy ◽  
Interleukin 15

BackgroundWith the poorest 5-year survival of all cancers, improving treatment for pancreatic cancer is one of the biggest challenges in cancer research. In this era of combination immunotherapies, we sought to explore the potential of combining both priming and activation of the immune system. To achieve this, we combined a CD40 agonist with interleukin-15 and tested its potential in pancreatic cancer.MethodsTwo different mouse models of pancreatic cancer were used to assess the potential of this combination regimen. Therefore, effects on tumour growth kinetics and survival were charted. Differential effects on immune signatures was investigated using RNA sequencing. Functional immune subset involvement was tested using different immune depletion experiments and multicolour flow cytometry in different relevant immune sites. Immune memory was checked using re-challenge experiments.ResultsWe demonstrated profound reduction in tumour growth and increased survival of mice with the majority of mice being cured when both agents were combined, including an unprecedented dose reduction of CD40 agonist without losing any efficacy (fig 1). RNA sequencing analysis showed involvement of natural killer cell and T cell mediated anti-tumour responses and the importance of antigen-presenting cell pathways. This combination resulted in enhanced infiltration of tumours by both cytotoxic T cells and natural killer cells, as well as a striking increase in the ratio of CD8+ T cells over T regulatory cells. We also observed a significant increase in numbers of dendritic cells in tumour draining lymph nodes, particularly CD103+ dendritic cells with cross-presentation potential. A critical role for CD8+ T cells and involvement of natural killer cells in the anti-tumour effect was highlighted. Importantly, strong immune memory was established, with an increase in memory CD8+ T cells only when both interleukin-15 and the CD40 agonist were combined.Abstract 453 Figure 1Tumour kinetics and survival in Panc02 (left) and KPC (right) pancreatic cancer mouse modelsConclusionsWe demonstrated profound synergistic anti-tumour effects upon combination of CD40 agonist and interleukin-15 treatment in mouse models of pancreatic cancer. This preclinical data supports initiation of a first-in-human clinical trial with this combination immunotherapy strategy in pancreatic cancer.

Intratumoral and Oncoviral Immunotherapy

2021 ◽  
Author(s):  
Rahul A. Sheth
Keyword(s):  
Treatment Strategy ◽  
Cancer Care ◽  
Therapeutic Agent ◽  
Checkpoint Inhibitor ◽  
Objective Response ◽  
Combination Immunotherapy ◽  
Image Guided ◽  
Checkpoint Inhibitor Therapy ◽  
Direct Delivery ◽  
Paradigm Shifting

AbstractImmunotherapy is a paradigm-shifting advance in cancer care, but despite their success, contemporary immunotherapy strategies are limited by several factors. The objective response rates to checkpoint inhibitor therapy remain below 50%, and the toxicities associated with systemically administered immunotherapies, particularly combination immunotherapy regimens, can be devastating. Intratumoral immunotherapies represent a burgeoning paradigm in immuno-oncology designed to address these limitations. The direct delivery of intratumoral immunotherapies can result in concentrations of the therapeutic agent at levels that would likely be far too toxic if administered systemically. In this review, I summarize the sound biological framework underlying intratumoral immunotherapies as well as provide an overview of the major categories of intratumoral agents currently under investigation. I also emphasize the components of this treatment strategy that are relevant for image-guided interventionalists based on existing clinical experience.

scholarly journals Combination immunotherapy for non-small cell lung cancer

1990 ◽  
Vol 99 (1) ◽  
pp. 8-13 ◽  
Author(s):  
Stephen C. Yang ◽  
Laurie Owen-Schaub ◽  
Ana Mendiguren-Rodriguez ◽  
Elizabeth A. Grimm ◽  
Waun K. Hong ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Combination Immunotherapy ◽  
Small Cell Lung

scholarly journals Role of dendritic cell metabolic reprogramming in tumor immune evasion

2020 ◽  
Vol 32 (7) ◽  
pp. 485-491 ◽  
Author(s):  
Michael P Plebanek ◽  
Michael Sturdivant ◽  
Nicholas C DeVito ◽  
Brent A Hanks
Keyword(s):  
Dendritic Cell ◽  
Metabolic Pathways ◽  
Checkpoint Inhibitor ◽  
Therapeutic Strategies ◽  
Metabolic Reprogramming ◽  
Combination Immunotherapy ◽  
Tumor Immune Evasion ◽  
Effector T Cell ◽  
Cell Responses

Abstract The dendritic cell (DC) is recognized as a vital mediator of anti-tumor immunity. More recent studies have also demonstrated the important role of DCs in the generation of effective responses to checkpoint inhibitor immunotherapy. Metabolic programming of DCs dictates their functionality and can determine which DCs become immunostimulatory versus those that develop a tolerized phenotype capable of actively suppressing effector T-cell responses to cancers. As a result, there is great interest in understanding what mechanisms have evolved in cancers to alter these metabolic pathways, thereby allowing for their continued progression and metastasis. The therapeutic strategies developed to reverse these processes of DC tolerization in the tumor microenvironment represent promising candidates for future testing in combination immunotherapy clinical trials.

Sign in / Sign up

Export Citation Format

Share Document